Jupiter Neurosciences (NASDAQ:JUNS) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 20 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $18.652 thousand which missed the analyst consensus estimate of $225.000 thousand by 91.71 percent.